Mascarenhas, J., Bradley, T. J., Scott, B. L., Yimer, H. A., Dougherty, S., Peng, L., Huang, F., Wan, Y., Feller, F., Rodolf, V., Ho, J., Berry, T., Kuykendall, A. T., Otoukesh, S. (2025). IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.6515